Literature DB >> 33603317

The effect of denosumab administration on bone metabolism for treatment of spinal metastasis.

Katsuhisa Kawanami1, Atsuhiko Hirasawa1, Masataka Deie1.   

Abstract

BACKGROUND: We investigated changes in bone metabolism markers over time for evaluating the effect of denosumab following administration to patients with spinal metastasis.
METHODS: Subjects of this study were 28 patients treated at the Department of Orthopedic Surgery at Aichi Medical University.
RESULTS: At 6 months after denosumab intervention, measured TRAP-5b values were significantly lower compared to pre-intervention values in both the osteosclerotic lesion and osteolytic lesion groups.
CONCLUSIONS: This change in bone metabolism marker values over time is one of the methods for evaluating the effect of treatment on bone tissue in cases of spinal metastasis.
© 2021 Published by Elsevier B.V. on behalf of Professor P K Surendran Memorial Education Foundation.

Entities:  

Keywords:  BAP; Denosumab administration; Spinal metastasis; TRAP-5b

Year:  2021        PMID: 33603317      PMCID: PMC7868681          DOI: 10.1016/j.jor.2021.01.009

Source DB:  PubMed          Journal:  J Orthop        ISSN: 0972-978X


  7 in total

1.  Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients.

Authors:  Chuanhao Tang; Yi Liu; Haifeng Qin; Xiaoyan Li; Wanfeng Guo; Jianjie Li; Weixia Wang; Lili Qu; Haixu Hu; Chunhong Xu; Li Zheng; Yaohua Huang; Bing Liu; Hongjun Gao; Jussi M Halleen; Xiaoqing Liu
Journal:  Clin Chim Acta       Date:  2013-09-19       Impact factor: 3.786

2.  Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline.

Authors:  A Berruti; L Dogliotti; R Bitossi; G Fasolis; G Gorzegno; M Bellina; M Torta; F Porpiglia; D Fontana; A Angeli
Journal:  J Urol       Date:  2000-10       Impact factor: 7.450

3.  Clinical outcome for patients of solitary bone only metastasis.

Authors:  Seiichi Hosaka; Hirohisa Katagiri; Yosuke Honda; Junji Wasa; Hideki Murata; Mitsuru Takahashi
Journal:  J Orthop Sci       Date:  2016-02-26       Impact factor: 1.601

4.  Evaluation of bone metabolic markers in breast cancer with bone metastasis.

Authors:  N Wada; M Fujisaki; S Ishii; T Ikeda; M Kitajima
Journal:  Breast Cancer       Date:  2001       Impact factor: 4.239

5.  Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.

Authors:  Matthew R Smith; Fred Saad; Robert Coleman; Neal Shore; Karim Fizazi; Bertrand Tombal; Kurt Miller; Paul Sieber; Lawrence Karsh; Ronaldo Damião; Teuvo L Tammela; Blair Egerdie; Hendrik Van Poppel; Joseph Chin; Juan Morote; Francisco Gómez-Veiga; Tomasz Borkowski; Zhishen Ye; Amy Kupic; Roger Dansey; Carsten Goessl
Journal:  Lancet       Date:  2011-11-15       Impact factor: 79.321

6.  Markers of bone turnover for the management of patients with bone metastases from prostate cancer.

Authors:  P Garnero; N Buchs; J Zekri; R Rizzoli; R E Coleman; P D Delmas
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

7.  New prognostic factors and scoring system for patients with skeletal metastasis.

Authors:  Hirohisa Katagiri; Rieko Okada; Tatsuya Takagi; Mitsuru Takahashi; Hideki Murata; Hideyuki Harada; Tetsuo Nishimura; Hirofumi Asakura; Hirofumi Ogawa
Journal:  Cancer Med       Date:  2014-07-10       Impact factor: 4.452

  7 in total
  1 in total

1.  Estimating survival and choosing treatment for spinal metastases: Do spine surgeons agree with each other?

Authors:  Quirina C B S Thio; Nuno Rui Paulino Pereira; Olivier van Wulfften Palthe; Daniel M Sciubba; Jos A M Bramer; Joseph H Schwab
Journal:  J Orthop       Date:  2021-11-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.